AbbVie Inc
ABBVToday
-2.35%
5 Days
+1.17%
1 Month
-4.92%
6 Months
+15.99%
Year to Date
-4.30%
1 Year
+25.09%
TradingKey Stock Score of AbbVie Inc
Currency: USD Updated: 2026-01-28Key Insights
AbbVie Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 247.76.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AbbVie Inc's Score
Support & Resistance
Score Analysis
Media Coverage
AbbVie Inc Highlights
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
Analyst Rating
AbbVie Inc News
Financial Indicators
EPS
Total revenue
AbbVie Inc Info
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
Related Instruments
Popular Symbols
